Osteoporosis is a chronic, progressive, skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility. Biological pathways leading to osteoporosis remain incompletely understood. The discovery of novel pathways for osteoporosis could lead to new preventive strategies or therapeutic targets. Fetuin-A is a hepatic-derived, serum protein that regulates calcium mineralization. We aimed to evaluate the correlation between serum Fetuin-A concentrations and bone mineral density (BMD) in postmenopausal women.52 postmenopausal women were enrolled in the current study, divided to 2 groups; Group I: 31 postmenopausal osteoporotic women, not on osteoporotic treatment, group II(controls): 21age-matched post-menopausal women with normal BMD. Exclusion criteria included; females with surgical menopause or secondary osteoporosis, those with acute infection, malignancy, myocardial infarction (MI) within the previous month, a history of severe trauma, surgery, burns, diabetes mellitus (DM), liver or kidney disease, , a history of smoking or alcoholism, patients taking steroids, anticonvulsants, chemotherapy,hormone replacement therapy (HRT), and L-Thyroxine. Basic laboratory investigations were done, plus parathyroid hormone(PTH), serum vitamin D3 levels, and serum Fetuin-A levels. Women in osteoporotic group had significantly lower BMI, vitaminDlevels, and higher PTH levels. Also, women in osteoporotic group had significantly lower Fetuin-A